The first major retatrutide clinical trial was published in the New England Journal of Medicine in 2023. It enrolled 338 adults with obesity but without diabetes, randomized them to receive retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg once weekly, or placebo, for 48 weeks. The results established retatrutide as the most potent weight-loss compound ever tested: 24.2% average weight loss on the 12 mg dose. The trial also established the graduated dosing schedule \u2014 2 mg to 4 mg to 8 mg to 12 mg over 12 weeks \u2014 that became the standard for all subsequent studies.<\/p>\n
Announced December 11, 2025, TRIUMPH-4 was the first Phase 3 trial to report results. It enrolled adults with obesity and knee osteoarthritis. The primary endpoint was weight loss at 68 weeks, with secondary endpoints measuring knee pain and physical function. The results: 28.7% average weight loss (71.2 pounds), plus statistically significant reduction in knee pain. This trial was important not just for the weight loss data, but for demonstrating that retatrutide could improve obesity-related comorbidities, which strengthens the case for regulatory approval.<\/p>\n
On May 21, 2026, Eli Lilly announced TRIUMPH-1 results. The 12 mg dose produced 28.3% weight loss at 80 weeks. Participants with a BMI of 35 or higher who stayed on the drug lost an average of 30.3% \u2014 85 pounds \u2014 at 104 weeks. The trial also showed improvements in waist circumference, systolic blood pressure, and glycemic control. These numbers exceeded analyst expectations and pushed retatrutide past the 30% weight loss milestone for the first time.<\/p>\n
The full TRIUMPH program includes eight Phase 3 trials. TRIUMPH-2 and TRIUMPH-3 are testing retatrutide in people with type 2 diabetes. TRIUMPH-5 is a weight maintenance trial for participants who lost weight on retatrutide and are randomized to continue the drug or switch to placebo. TRIUMPH-6 through -8 cover additional obesity and cardiovascular outcome populations. Results are expected through 2026 and 2027, and the complete data package will form the basis of the FDA New Drug Application.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Phase 2 Foundation: NEJM 2023 The first major retatrutide clinical trial was published in the New England Journal of Medicine in 2023. It enrolled 338 adults with obesity but without diabetes, randomized them to receive retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg once weekly, or placebo, for 48 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/19","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19"}],"version-history":[{"count":0,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/19\/revisions"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}